[1] | Koffie RM, Hyman BT and Spires-Jones TL (2011) Alzheimer’s diseases: synapses gone cold. Molecular Neurodegeneration 6:63. Doi:10.1186/1750-1326-6-63 |
[2] | Yassin M, Armaly Z, Bisharat B, Bowirrat A (20-13) Biomarkers for Alzheimer’s Disease: Imagination or Reality-View and Review! Journal of Behavioral and Brain Science 3: 393-402. |
[3] | Guerreiro RJ, Gustafson DR, Hardy J (2012) The genetic architecture of Alzheimer’s disease: Beyond APP, PSENs AND APOE. Neurobiol Aging 33(3): 437–456. |
[4] | Bowirrat A., Friedland RP., Farrer L., Baldwin C., Korczyn A (2002) Genetic and Environmental Risk factors for Alzheimer’s disease in Israeli Arabs. Journal of Molecular Neuroscience 19(1-2):239-245. |
[5] | Waldemar G, Dubois B, Emre M (2007) Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology 14(1):e1–e26. |
[6] | Clifford RJ, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9(1): 119. doi: 10.1016/S1474-4422(09)70299-6. |
[7] | Jack CR, Holtzman DM (2013) Biomarker modeling of Alzheimer's disease. Neuron 80(6):1347-58. |
[8] | Leszek J, Sochocka M, Gąsiorowski K. Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer's disease (2012) J Neurol Sci 15;323(1-2):25-32. doi: 10.1016/j.jns.2012.09.010. Epub 2012 Sep 29. Review. |
[9] | Iadecola C (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120(3): 287–296. doi:10.1007/s00401-010-0718-. |
[10] | Grand Jacob HG, Caspar S, MacDonald Stuart WS (2011) Clinical features and multidisciplinary approaches to dementia care. Journal of Multidisciplinary Healthcare 4 125–147. |
[11] | Iadecola C, Park L, Capone C (2009) Threats to the Mind Aging, Amyloid, and Hypertension. Stroke 40(3 Suppl): S40–S44. |
[12] | Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD (1999) Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet 354:919–920. |
[13] | Meng Y, Baldwin CT, Bowirrat A, Inzelberg R, Waraska K, Friedland RP, Farrer LA (2006) Association of Polymorphism in the Angiotensin-converting Enzyme Gene With Alzheimer's Disease in an Israeli-Arab Community. Am J Hum Genet 78:871-877. |
[14] | Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 62:.1148–1155. |
[15] | Jellinger KA (2013) Pathology and pathogenesis of vascular cognitive impairment—a critical update. Front Aging Neurosci 5: 17. |
[16] | Jellinger KA (2007) The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 113(4): 349–388. |
[17] | Kalaria RN, Ballard C (1999) Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Disease and Associated Disorders 13(3):S115–S123. |
[18] | Jellinger KA, Attems J (2010) Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 119:421–433. [PubMed] |
[19] | Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT, and Federico A (2010) “CSF Biomarkers Profile in CADASIL—A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder,” International Journal of Alzheimer’s Disease Article Volume 2010, ID 959257, 6 pages. doi:10.4061/2010/959257. |
[20] | Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Moody DM, O’Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennet DP, Fisher M, Ogata J, Kokmen E, Bermejo F, Wolf PA, Gorelick PB, Bick KL, Pajeau AK, Bell MA, DeCarli C, Culebras A, Korczyn AD, Bogousslavsky J, Hartman A, Scheinberg P (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43: 250 – 260. |
[21] | Marchesi VT (2014) Alzheimer's disease and CADASIL are heritable, adult-onset dementias that both involve damaged small blood vessels. Cell Mol Life Sci 71(6):949-55. doi: 10.1007/s00018-013-1542-7. Epub 2013 Dec 31. |
[22] | Xinzhen Yin, Dingwen Wu, Jinping Wan, Shenqiang Yan, Min Lou, Guohua Zhao, Baorong Z (2014) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: Phenotypic and mutational spectrum in patients from mainland China. International Journal of Neuroscience 8:1-22. |
[23] | Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cecillion M, Marechal E, Maciazek J, Vayssiere C, Cruaud C, Cabanis EA, Ruchoux MM, Weissenbach J, Bach JF, Bousser MG, Tournier-Lasserve E (1996) Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 24:383:707-10. |
[24] | Goebel HH, Meyermann R, Rosin R, Schlote W (1997) Characteristic morphologic manifestation of CADASIL, cerebral autosomal- dominant arteriopathy with subcortical infarcts and leukoencephalopathy, in skeletal muscle and skin. Muscle Nerve 20:625–7. |
[25] | LaPoint SF, Patel U, Rubio A (2000) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Adv Anat Pathol 7(5): 307-21. |
[26] | Malandrini A, Gaudiano C, Gambelli S (2007) Diagnostic value of ultrastructural skin biopsy studies in CADASIL. Neurology 68(17):1430-1432. |
[27] | Bowirrat A (2014) The Pathogenesis of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL, OMIM #125310). Ann Clin Cytol Pathol 1(1): 1002. |
[28] | Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Möller HJ (2004) Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 111(3): 247–272. doi:10.1007/s00702-003-0065-z. |
[29] | Frangogiannis NG (2012) “Biomarkers: Hopes and Challenges in the Path from Discovery to Clinical Practice,” Transla-tional Research 159(4): 197-204. doi:10.1016/j.trsl. 2012.01.023. |
[30] | Shaw M, Korecka M, Clark CM, Lee VMY and Trojanowski JQ (2007) “Biomarkers of Neurodegeneration for Diagnosis and Monitoring Therapeutics,” Nature Reviews Drug Discovery 6(4): 295-303. doi:10.1038/nrd2176. |
[31] | Downing G (2001) “Biomarkers Definitions Working Group. Biomarkers and Surrogate Endpoints,” Clinical Pharma- cology & Therapeutics 69; 89-95. |
[32] | Lee J, Devanarayan V, Barrett U, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M and Duan L (2006) “Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement,” Pharmaceutical Research 23(2): 312-328. doi:10.1007/s11095-005-9045-3 |
[33] | Frank R and Hargreaves R (2003) “Clinical Biomarkers in Drug Discovery and Development,” Nature Reviews Drug Dis- covery 2(7): 566-580. doi:10.1038/nrd1130 |
[34] | Harald H, Simone L and Khachaturian ZS (2012) “Develop- ment of Biomarkers to Chart All Alzheimer’s Disease Stages: The Royal Road to Cutting the Therapeutic Gor- dian Knot,” Alzheimer’s & Dementia 8(4): 312-336.doi:10.1016/j.jalz.2012.05.2116. |
[35] | Dhanasekaran SM (2001) “Delineation of Prognostic Biomar- kers in Prostate Cancer,” Nature 412(6849): 822-826. doi:10.1038/35090585 |
[36] | Wagner PD, Maruvada P and Srivastava S (2004) “Molecular Diagnostics: A New Frontier in Cancer Prevention,” Ex- pert Review of Molecular Diagnostics 4(4): 503-511. doi:10.1586/14737159.4.4.503. |
[37] | Gerde P, Muggenburg BA, Stephens T, Lewis JL, Pyon KH and Dahl AR (1998) “A Relevant Dose of 4-(Me- thylnitrosamino)-1-(3-pyridyl)-1-butanone Is Extensively Metabolized and Rapidly Absorbed in the Canine Tra- cheal Mucosa,” Cancer Research 58(7): 1417-1422. |
[38] | Prashanthi V (2010) “Effect of Apolipoprotein E on Biomarkers of Amyloid Load and Neuronal Pathology in Alzheimer Disease,” Annals of Neurology 67(3): 308-316. |
[39] | Johnston JA and Hill M (2011) “The Risk and Gamble We Take with Our Patients on Dopamine Agonists,” Journal of Neurology, Neurosurgery & Psychiatry 83(3): e1-e1. doi:10.1136/jnnp-2011-301993.155. |
[40] | Golias CH (2005) “Adhesion Molecules in Cancer Invasion and Metastasis,” Hippokratia 9(1): 106-114. |
[41] | Kader HA, Tchernev VT, Satyaraj E, Lejnine S, Kotler G, Kingsmore SF and Patel D (2005) “Protein Microar- ray Analysis of Disease Activity in Pediatric Inflamma- tory Bowel Disease Demonstrates Elevated Serum PLGF, IL-7, TGF-β1, and IL-12p40 Levels in Crohn’s Disease and Ulcerative Colitis Patients in Remission versus Ac- tive Disease,” The American Journal of Gastroenterology 100(2): 414-423. doi:10.1111/j.1572-0241.2005.40819.x. |
[42] | Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals O, Burkhard G and Sanchez JC (2003) “A Panel of Cerebrospinal Fluid Potential Biomarkers for the Diagno- sis of Alzheimer’s Disease,” Proteomics 3(8): 1486-1494. doi:10.1002/pmic.200300470 |
[43] | Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E and Hajak G (2005) “Cerebrospinal Fluid tau and β- Amyloid in Alzheimer Patients, Disease Controls and an Age-Matched Random Sample,” Neurobiology of Aging 27(9): 1202-1211. doi:10.1016/j.neurobiolaging.2005.06.005 |
[44] | Hartmann T, Bieger SC, Brühl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K (1997) "Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides". Nat Med 3(9): 1016–20. doi:10.1038/nm0997-1016. PMID |
[45] | Allam AR, Kiran KR, Hanuman T (2008) Bioinformatic analysis of Alzheimer's. Disease using functional protein sequences. J Proteomics Bioinform 1: 036–042. |
[46] | Wang R, Wang B, He W, Zheng H (2006) Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. J Biol Chem 281:15330–15336. |
[47] | Kessels HW, Nguyen LN, Nabavi S, Malinow R (2010) The prion protein as a receptor for amyloid- beta. Nature 466: E3–E4. |
[48] | Tomic JL, Pensalfini A, Head E, Glabe CG (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35:352–358. |
[49] | Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laurén J, Gimbel ZA (2010) Memory impairment in transgenic Alzheimer mice requires cellular prion protein J Neurosci 30: 6367–6374. |
[50] | Yang M, Virassamy B, Vijayaraj SL, Lim Y, Saadipour K, Wang YJ (2013) The intracellular domain of sortilin interacts with amyloid precursor protein and regulates its lysosomal and lipid raft trafficking. PLoS ONE 8(5): e63049 |
[51] | Butler D and Bahr BA (2006) “Oxidative Stress and Lyso- somes: CNS-Related Consequences and Implications for Lysosomal Enhancement Strategies and Induction of Autophagy,” Antioxidants & Redox Signaling 8(1-2): 185-196. |
[52] | Avila J, Lucas JJ, Perez M, Hernandez F (2004) Role of tau protein in both physiological and pathological conditions. Physiol Rev 84: 361–384. |
[53] | Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ and Younkin SG (2007) “Associa- tion of Low Plasma Abeta42/Abeta40 Ratios with In- creased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease,” Archives of Neurology 64(3): 354.doi:10.1001/archneur.64.3.354. |
[54] | Blennow K, Vanmechelen E and Hampel H (2001) “CSF To- tal tau, Ab42 and Phosphorylated tau Protein as Bio- markers for Alzheimer’s Disease” Molecular Neurobiol- ogy 24(1-3): 87-97. |
[55] | Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC Holtzman DM (2006) “Inverse Relation between in Vivo Amy- loid Imaging Load and Cerebrospinal Fluid Abeta42 in Humans,” Annals of Neurology 59(3): 512-519. doi:10.1002/ana.20730 |
[56] | Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC and Holtzman DM (2007) “Cerebrospinal Fluid tau/ beta-Amyloid(42) Ratio as a Prediction of Cognitive De- cline in Nondemented Older Adults,” Archives of Neu- rology 64(3): 343-349. doi:10.1001/archneur.64.3.noc60123 |
[57] | Sjögren M, Davidsson P and Aallin A (2002) “Decreased CSF β-Amyloid42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β- Amyloid Induced by separate mechanisms,” Dementia and Geriatric Cognitive Disorders 13: 112-118. doi:10.1159/000048642. |
[58] | Strozyk D, Blennow K, White LR and Launer LJ (2003) “CSF Aβ42 Levels Correlate with Amyloid-Neuropatho- logy in a Population-Based Autopsy Study,” Neurology 60(4): 652-656. doi:10.1212/01.WNL.0000046581.81650.D0 |
[59] | Hachinski VC, Bowler JV (1993) Vascular dementia. Neurology 43:2159–2160. |
[60] | Chui HC, Victoroff JI, Margolin D (1992) Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 42:473–480. |
[61] | Jellinger KA (2008) Morphologic diagnosis of “vascular dementia”—a critical update. J Neurol Sci 270:1–12. |
[62] | Erkinjuntti T, Gauthier S (2009) The concept of vascular cognitive impairment. Front Neurol Neurosci 24:79–85. |
[63] | Breteler MM (2000) Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol Aging 21:153–160. |
[64] | Iadecola C, Gorelick PB (2003) Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 34:335–337. |
[65] | Kalaria RN (2000) The role of cerebral ischemia in Alzheimer’s disease. Neurobiol Aging 21:321–330. |
[66] | Nagy Z, Esiri MM, Jobst KA (1997) The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 56:165–170. |
[67] | Snowdon DA, Greiner LH, Mortimer JA (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277:813–817. |
[68] | Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci 5:347–360. |
[69] | Koike MA, Green KN, Blurton-Jones M, LaFerla FM (2010) Oligemic hypoperfusion differentially affects tau and amyloid-{beta} Am J Pathol 177(1): 300-310. doi: 10.2353/ajpath.2010.090750. [PMC free article] [PubMed] |
[70] | Li L, Zhang X, Yang D (2009) Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol Aging 30:1091–1098. [PubMed] |
[71] | Tesco G, Koh YH, Kang EL (2007) Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 54:721–737. [PMC free article] [PubMed] |
[72] | Cirrito JR, Yamada KA, Finn MB (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48:913–922. [PubMed] |
[73] | Deane R, Wu Z, Sagare A (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333–344. [PubMed] |
[74] | Pfefferkorn T, von Stuckrad-Barre S, Herzog J, Gasser T, Hamann GF, Dichgans M. Reduced cerebrovascular CO(2) reactivity in CADASIL: a transcranial Doppler sonography study. Stroke 32: 17–21. |
[75] | Morris M, Maeda S, Vossel K and Mucke L (2011) “The Many Faces of Tau,” Neuron 70(3): 410-426. doi:10.1016/j.neuron.2011.04.009. |
[76] | Buée L, Bussiere T, Buee-Scherrer V, Delacourte A and Hof PR (2000) “Tau Protein Isoforms, Phosphorylation and Role in Neurodegenerative Disorders,” Brain Re- search Reviews 33(1): 95-130. doi:10.1016/S0165-0173(00)00019-9. |
[77] | Feijoo C, Campbell DG, Jakes R, Goedert M and Cuenda A (2005) “Evidence That Phosphorylation of the Micro- tubule-Associated Protein Tau by SAPK4/p38δ at Thr50 Promotes Microtubule Assembly,” Journal of Cell Sci- ence 118(2): 397-408. doi:10.1242/jcs.01655. |
[78] | Boekhoorn K, Terwel D, Biemans B, Borghgraef P, Wiegert O, Ramakers GJ and Lucassen PL (2006) “Improved Long-Term Potentiation and Memory in Young tau- P301L Transgenic Mice before Onset of Hyperphos- phorylation and Tauopathy. J Neurosci 26(13): 3514-3523. |
[79] | Vandermeeren M, Mercken M and Vanmechelen E (1993) “Detection of τ Proteins in Normal and Alzheimer’s Dis- ease Cerebrospinal Fluid with a Sensitive Sandwich En- zyme-Linked Immunosorbent Assay. Journal of Neuro- chemistry 61: 1828-1834.doi:10.1111/j.1471-4159.1993.tb09823.x. |
[80] | Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K and Minthon L (2006) “Association between CSF Biomarkers and Incipient Alzheimer’s Disease in Patients with Mild Cognitive Impairment: A Follow-Up Study. The Lancet Neurology 5(3): 228-234.doi:10.1016/S1474-4422(06)70355-6. |
[81] | Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals O, Burkhard G and Sanchez JC (2003) “A Panel of Cerebrospinal Fluid Potential Biomarkers for the Diagno- sis of Alzheimer’s Disease. Proteomics 3(8): 1486-1494. doi:10.1002/pmic.200300470. |
[82] | Lanari A and Parnetti L (2009) “Cerebrospinal Fluid Bio- markers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Rou- tine Clinical Setting. The Scientific World Journal 9: 961-966. doi:10.1100/tsw.2009.106. |
[83] | Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M and Blennow K (2009) “CSF Biomarkers and Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment,” The Journal of the American Medical Association 302(4): 385-393. doi:10.1001/jama.2009.1064. |
[84] | Zanusso G, Fiorini M, Righetti PG and Monaco S (2011) “Specific and Surrogate Cerebrospinal Fluid Markers in Creutzfeldt—Jakob Disease,” Advances in Neurobiology 2: 455-467. |
[85] | Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT and Federico A, “CSF Levels of β-Amyloid 1-42, Tau and Phosphorylated Tau Protein in CADASIL,” European Journal of Neurology 15(11): 1252-1255.doi:10.1111/j.1468-1331.2008.02277. |
[86] | Stanford PA, Halliday GM, Brooks WS, Kwok JB, Storey CE, Creasey H and Schofield PR (2011) “Progressive Supranuclear Palsy Pathology Caused by a Novel Silent Mutation in Exon 10 of the Tau Gene Ex- pansion of the Disease Phenotype Caused by Tau Gene Mutations,” Brain 123(5): 880-893. |
[87] | Cleveland DW, Hwo SY and Kirschner MW (1977) “Physical and Chemical Properties of Purified Tau Factor and the Role of Tau in Microtubule Assembly,” Journal of Molecular Biology 116(2): 227- 247. |
[88] | Morris M, Maeda S, Vossel K and Mucke L (2011) “The Many Faces of Tau,” Neuron 70(3): 410-426. doi:10.1016/j.neuron.2011.04.009. |
[89] | Buée L, Bussiere T, Buee-Scherrer V, Delacourte A and Hof PR (2000) “Tau Protein Isoforms, Phosphorylation and Role in Neurodegenerative Disorders,” Brain Re- search Reviews 33(1): 95-130. |
[90] | Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H and Trojanowski JQ (2009) “Total and Phosphory- lated Tau Protein as Biological Markers of Alzheimer’s Disease,” Experimental Gerontology 45(1): 30-40.doi:10.1016/j.exger.2009.10.010 |
[91] | Stenset V, Johnsen L, Kocot D (2006) Associations between white matter lesions, cerebrovascular risk factors, and low CSF Aβ42. Neurology 67(5):830–833. [PubMed] |
[92] | Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I (2013) Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis. J Neurol 260(11):2722-7. doi: 10.1007/s00415-013-7047-3. |